Laboratoires Vivacy to acquire a majority stake Burgeon Biyoteknoloji from Diffusion Capital Partners.

Laboratoires Vivacy, renowned for its dermal fillers, produced using its patented IPN-Like Technology, agreed to acquire a 50% majority stake of Burgeon Biyoteknoloji, an innovative biotechnology company, from Diffusion Capital Partners, a venture capital fund manager. Financial terms are not disclosed. “Thanks to our innovative technologies, pioneering vision, and proven global success, we have established a strategic partnership with VIVACY, a prominent player in the industry. We are thrilled to have signed a significant global collaboration that reflects the value we create and the strength of our groundbreaking technologies. Through this partnership, we will continue to lead the industry and deliver innovative solutions. Together with VIVACY, we will break new ground, develop future-defining solutions, and achieve global success.” Levent Mete Özgürbüz, Burgeon Biotechnology Founder and Managing Partner.